ArticleJournal of neuroinflammation2025
Pharmacological inhibition of the cGAS-STING pathway suppresses microglia pyroptosis in sepsis-associated encephalopathy.
Article in Journal of neuroinflammation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- The cGAS-STING Pathway Drives Astrocyte-Mediated Demyelination in Multiple Sclerosis Through Clusterin Secretion.CNS neuroscience & therapeutics · 2026Article
- [Thymosin β4 inhibits pyroptosis in BV2 microglial cells: a mechanistic studyZhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2026Article
- Mitochondrial dysfunction in neonatal brain injury: from molecular mechanisms to therapeutic interventions.Journal of translational medicine · 2026Review
- Endothelial-specific Ezh2 deficiency exacerbates blood-brain barrier dysfunction and neuroinflammation in sepsis-associated encephalopathy.Journal of neuroinflammation · 2026Article
- HSP60 Mediates NLRP3 Inflammasome-Dependent Microglial Pyroptosis Via the TLR4/MyD88/NF-κB Signaling Axis After Subarachnoid Hemorrhage.Inflammation · 2026Article
- Crosstalk of mitochondrial dysfunction and macrophage polarization in sepsis.Frontiers in immunology · 2026Review
- METTL3-Mediated m6A Modification of lncRNA-0949 Drives Microglial Inflammation in an vitro Model of Sepsis-Associated Encephalopathy.Journal of inflammation research · 2026Article
- Cell-free DNA in sepsis: from molecular insights to clinical management.Military Medical Research · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Sepsis-associated encephalopathy (SAE) presents significant challenges in clinical management due to its association with cognitive impairments and high mortality rates. This study aims to elucidate the molecular mechanisms underlying microglial pyroptosis and the stimulator of interferon genes (STING) signaling pathway in SAE, with a focus on identifying potential therapeutic targets. Employing the cecal ligation and puncture (CLP) model - the gold-standard polymicrobial sepsis model that faithfully replicates human sepsis progression - in C57BL/6J mice, we assessed the effects of various pharmacological agents, including the pyroptosis inhibitor dimethyl fumarate (DMF), the STING inhibitor C176, and the mitochondrial protectant idebenone, on cognitive and behavioral outcomes in SAE mice. Results indicated that DMF significantly prevented microglial pyroptosis, reduced inflammatory cytokine levels in the hippocampus, thereby enhancing survival rates and cognitive function. Additionally, inhibition of microglial pyroptosis through C176 effectively inhibited the STING signaling pathway, consequently reducing microglial pyroptosis and ameliorating behavioral symptoms associated with SAE. Furthermore, idebenone was observed to exert mitochondrial protection and inhibit STING-mediated pyroptosis of microglia, leading to an improvement in behavioral symptoms in the SAE model. In conclusion, our findings underscore the pivotal roles of pyroptosis and the STING signaling pathway in the pathophysiology of SAE, suggesting that targeting these mechanisms may provide promising therapeutic avenues for improving cognitive recovery in sepsis patients. Future studies should focus on elucidating the underlying molecular mechanisms and exploring their clinical viability in the management of SAE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.